Vantrexa · NSCLC · France · Radiation oncologist · captured by James Whitfield on 31 Mar 2026 · reviewed by Dr. Sophie Laurent on 06 Apr 2026
Verbatim as captured; never edited
Radiation oncologist at Gustave Roussy raised chemotherapy-free first line during a congress meeting. They noted that colleagues in their network share the view.
Human-approved by Dr. Sophie Laurent on 06 Apr 2026
Chemotherapy-free first line: interest in collaboration reported by radiation oncologist (FR).
helixor-private-llm-2026.05 · generated 31 Mar 2026, 10:00 UTC
AI summary
Chemotherapy-free first line raised by radiation oncologist; suggest routing to Clinical Development.
Source spans used by the model
Radiation oncologist at Gustave Roussy raised chemotherapy-free first line during a congress meeting. They noted that colleagues in their network share the view.
| Field | AI suggestion | Final (human-approved) |
|---|---|---|
| Category | Efficacy | Efficacy |
| Function | Clinical Development | Clinical Development |
| Priority | Medium | Medium |
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 1 | 20% | 4.0 |
| Strategic alignment | 3 | 20% | 12.0 |
| Scientific importance | 3 | 15% | 9.0 |
| Urgency | 1 | 15% | 3.0 |
| Novelty | 2 | 10% | 4.0 |
| Actionability | 4 | 10% | 8.0 |
| Confidence | 4 | 5% | 4.0 |
| Breadth of occurrence | 1 | 5% | 1.0 |
| Total | Medium 45 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
31 Mar 2026 · Dr. William Ivanova, Gustave Roussy · MSL James Whitfield
Insight
Reviewed 06 Apr 2026 by Dr. Sophie Laurent
Action
Initiative
Decision
Outcome
Closure
Incorporated into evidence-generation plan.